GRIN1
Glutamate receptor ionotropic, NMDA 1
As of the edition of 20 October 2026, GRIN1 (glutamate receptor ionotropic, NMDA 1, UniProt Q05586) has 21 drugs tested at it and 29 companies on the list, 8 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q05586
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 84
- Disease areas
- Mental health; Nervous system; Cancer; Chemically induced; Injuries; Lungs and airways; Inherited and neonatal; Infections
- Registered trials of its drugs
- 1,373
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 2 |
| Went quiet | 6 |
| Stopped | 6 |
| Status not established | 1 |
| Total | 21 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ketamine | Marketed | Phase 4 | none listed |
| Esketamine | Marketed | Phase 4 | Ends 2028 |
| Memantine | Marketed | Phase 4 | none listed |
| Amantadine | Marketed | Phase 4 | none listed |
| Acamprosate | Marketed | Phase 4 | none listed |
| Rapastinel | Stopped | Phase 3 | none listed |
| Neramexane | Stopped | Phase 3 | none listed |
| Lanicemine | Went quiet | Phase 2 | none listed |
| AV-101 | Stopped | Phase 3 | none listed |
| Radiprodil | Active | Phase 3 | none listed |
| Apimostinel | Active | Phase 2 | none listed |
| Rislenemdaz | Went quiet | Phase 2 | none listed |
12 of 21 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Route B | 7 |
| Engaged | 6 |
| Undetermined | 8 |
| Total on the list | 29 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| AstraZeneca | Route A |
| Viatris | Route B |
The other 26 companies at GRIN1
In the product29 companies in all; 26 are not named here, and no score is.
See the 29 companies at GRIN1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.